- Johnson & Johnson announces a $55 billion U.S. investment by early 2029.
- Two new manufacturing facilities will be built in Pennsylvania and North Carolina.
- A $2 billion biologics facility in Wilson, NC, will create 5,000 jobs.
- A new 160,000+ sq ft biopharmaceutical site in Holly Springs, NC, will create 120 jobs.
Agreement with U.S. Government
Johnson & Johnson has reached a voluntary agreement with the U.S. government to improve access to medicines and reduce costs for American patients. This agreement exempts the company's pharmaceutical products from tariffs and aligns with the administration's goals to lower drug prices.
TrumpRx.gov Participation
The company will participate in TrumpRx.gov, a platform allowing American patients to purchase medicines at significantly discounted rates. This initiative aims to provide U.S. patients with access to medicines at prices comparable to those in other developed countries.
$55 Billion U.S. Investment
Johnson & Johnson is committed to a $55 billion investment in U.S. manufacturing, research, and development by early 2029. This investment includes the construction of new manufacturing facilities and the expansion of existing ones to support the production of advanced medicines in the U.S.
New Manufacturing Facilities
The company is building two new manufacturing facilities: a next-generation cell therapy site in Pennsylvania and a state-of-the-art drug product facility in North Carolina. Additionally, a $2 billion biologics manufacturing facility in Wilson, North Carolina, is under construction, expected to create approximately 5,000 jobs.
Expansion in North Carolina
Johnson & Johnson has secured a new 160,000+ square foot biopharmaceutical manufacturing site in Holly Springs, North Carolina. This $2 billion commitment over the next decade will create around 120 new jobs. Further U.S. investments are anticipated later this year.
